SCHEMBL582016

SCHEMBL582016

CCOC(=O)CC(=O)[C@@H]1CCN(C(=O)OC)[C@H](c2ccc(F)cc2F)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
TDP1 Q9NUW8 1/20 0.44
P2RX7 Q99572 1/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 1/20 0.37
HCRTR2 O43614 2/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 2/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL581963 1.00 ALDH1A1 (0.44) ALDH1A1TDP1P2RX7MAPTKDM4E
SCHEMBL581183 0.90 TLR4 (0.40) ALDH1A1TDP1KDM4EMEN1KMT2A
SCHEMBL3078690 0.90 MGLL (0.38) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL581707 0.90 MGLL (0.38) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL593617 0.90 MGLL (0.38) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL580854 0.89 ALDH1A1 (0.38) ALDH1A1TDP1KDM4EMEN1KMT2A
SCHEMBL3069384 0.89 ALDH1A1 (0.38) ALDH1A1TDP1KDM4EMEN1KMT2A
SCHEMBL599010 0.89 CYP11B1 (0.39) ALDH1A1KDM4EHTTTMEM97SIGMAR1
SCHEMBL581169 0.89 CYP11B1 (0.39) ALDH1A1KDM4EHTTTMEM97SIGMAR1
SCHEMBL581644 0.89 CYP11B1 (0.39) ALDH1A1KDM4EHTTTMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 ALDH1A1 2598/4885TDP1 3355/4885P2RX7 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.